# INTUITT-NF2: brigatinib in NF2-related schwannomatosis with progressive tumours

Source: https://onco.cc/key-papers/paper-intuitt-nf2-brigatinib-plotkin-nejm-2024/  
OnCo record `paper-intuitt-nf2-brigatinib-plotkin-nejm-2024` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

In people with the inherited condition NF2 whose nerve and brain-lining tumours were growing despite earlier treatment, the kinase inhibitor brigatinib shrank some tumours, slowed the growth of all types and improved hearing in a third of affected ears without serious toxicity.

## Summary

First sub-study of the adaptive platform trial INTUITT-NF2: 40 patients (median age 26) with NF2-related schwannomatosis and progressive target tumours (10 vestibular schwannomas, 8 non-vestibular schwannomas, 20 meningiomas, 2 ependymomas) received brigatinib.

After a median follow-up of 10.4 months, 10 percent of target tumours and 23 percent of all tumours had a radiographic response, with meningiomas and non-vestibular schwannomas benefiting most; annualised growth rates fell for all tumour types; hearing improved in 35 percent of eligible ears; pain scores fell; and there were no grade 4 or 5 treatment-related adverse events.

## Fields

- Kind: Key paper
- Last checked: 2026-09-22
- Journal: New England Journal of Medicine
- Year: 2024
- DOI: 10.1056/NEJMoa2400985
- Authors: Plotkin SR, Yohay KH, Nghiemphu PL, et al.
- Findings: Radiographic response in 10 percent (95% CI 3 to 24) of target tumours and 23 percent (16 to 30) of all tumours.; Annualised growth rates decreased for every tumour type during treatment.; Hearing improvement in 35 percent (95% CI 20 to 53) of eligible ears; no grade 4 or 5 treatment-related adverse events.
- What it means: Brigatinib is the first drug shown to act across the tumour types of NF2-related schwannomatosis and is now offered for progressive tumours; the platform design lets further drugs be tested against the same benchmark.
- Caveats: Single-arm sub-study with short follow-up; responses were modest by size criteria.; Vestibular schwannomas responded less than meningiomas and non-vestibular schwannomas.

## Sources

- N Engl J Med 2024: https://doi.org/10.1056/NEJMoa2400985
- PubMed: https://pubmed.ncbi.nlm.nih.gov/38904277/

## Connected records

- cancers: [Meningioma](https://onco.cc/cancers/meningioma/), [Vestibular schwannoma (acoustic neuroma)](https://onco.cc/cancers/vestibular-schwannoma/)
- drugs: [Brigatinib](https://onco.cc/drugs/brigatinib/)
- trials: [INTUITT-NF2](https://onco.cc/trials/intuitt-nf2/)
- journals: [New England Journal of Medicine](https://onco.cc/journals/nejm/)

---
JSON: https://onco.cc/api/v1/entities/paper-intuitt-nf2-brigatinib-plotkin-nejm-2024.json